Ablative CO2 Laser Effective for Asian Skin Rejuvenation

But higher hyperpigmentation rate found than with non-ablative fractional resurfacing

WEDNESDAY, Nov. 24 (HealthDay News) -- Fractional ablative carbon dioxide (CO2) laser resurfacing is minimally to moderately effective in rejuvenating the skin of Asian patients, but causes a higher rate of post-inflammatory hyperpigmentation (PIH) than non-ablative fractional resurfacing (NA FR) laser treatment, according to a clinical report published in the November issue of Lasers in Surgery and Medicine.

Nicola P.Y. Chan, of the University of Hong Kong, and colleagues gave nine Chinese patients with facial acne scars or photoaging a full-face treatment with a 10,600 nm fractional CO2 laser. Up to six months post-treatment, the researchers assessed skin texture, laxity, wrinkles, pore size, pigmentation, and adverse effects.

The researchers found significant -- though only mild to moderate -- improvements in skin texture, skin laxity, wrinkles, enlarged pores, and acne scars. The PIH rate was 55.5 percent at one month after treatment, 37.5 percent at three months, and 11.1 percent at six months, which were higher PIH rates than the 7.1 to 13 percent rates reported with NA FR. Eighty-six percent of patients said they were satisfied or very satisfied overall with the ablative fractional resurfacing treatment.

"Ablative fractional CO2 laser resurfacing was overall safe and effective for skin rejuvenation and acne scars in Asians. However, in view of the high post-inflammatory rate and the statistically significant but only mild to moderate improvement after a single treatment as observed in this study, there is a need to review the current role of fractional ablative CO2 laser treatment as compared to fractional non-ablative for skin rejuvenation and acne scar treatment in Asians," the authors write.

One study author disclosed being a stock holder of Solta Medical, which manufactures the equipment used in the study.

Full Text (subscription or payment may be required)

Physician's Briefing